Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 0.67% 7.55 7.30 7.80 7.55 7.525 7.53 132,930 12:59:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 16

Eden Research Share Discussion Threads

Showing 7076 to 7097 of 8350 messages
Chat Pages: Latest  286  285  284  283  282  281  280  279  278  277  276  275  Older
DateSubjectAuthorDiscuss
15/5/2019
20:40
Commercial news about these will give it a nudge. Molluscicide news Insecticide news Wider Mevalone application Post Harvest/ Seipro Cedroz registrations. EGTOP Organic announcement Eugenol / Thymol / Geraniol Strategic update/strategic investor/ Bayer news TT news Bayer / TT parallel delay revelation.. Sustaine news from Sipcam and collaborators / Eastman Field crops trials Cotton/wheat/soybean / 'highly potent active agent encapsulated' news Anti-microbial news Xinova Any pipeline news
supersonico
15/5/2019
19:37
All this was said 10 years ago by an excited Sir Ben and Brooks, and that after a previous 10 years of hype People just get fed up with the endless stories which never seem to come to fruition The only thing that will move the shares now is SUBSTANTIAL AND INCREASING REVENUE
sandcrab2
15/5/2019
18:49
A damp squib from a company intent on publicly dampening expectations..
supersonico
15/5/2019
18:24
Chrischas, while I think that share price predictions have been far too optimistic on here, I remain of the opinion that this year should prove a threshold period, assuming US clearance for cedroz and mevalone, and hopefully, TT & Bayer. Look for the impact on revenues, which I believe will begin to show an exponential curve, albeit from a low base. That won't be ignored. Sadly, the AGM seems to have been a damp squib.
brucie5
15/5/2019
16:33
Well I really do believe that they are keeping the price low..Get an alliance with a Private company ,throw something to another big company and keep raking in some good remuneration. Share holders , wot shareholders? Well maybe they were 2 busy expanding the company ,getting themselves seen in the market to spend much time on the AGM.Eden that paradise on the sunny horizon.Always just too far but still there. I said 20-25p by September .Silly me that was far too optimistic
chrischas
15/5/2019
16:32
Shore cap are the whipping boy sat in a Incongruent Room that is almost full with Elephants.
supersonico
15/5/2019
15:08
Eden, the Snail in the Garden I see Michael Walters has it spot on this time. There is a great deal of frustration around the Eden share price! The problem is that Eden is not allowed to tell common garden investors what is in the shore cap report even though as owners of the company we have paid for it via fees to the brokers! Fairly basic Proactive chats are no substitutions for real projections (that we all can see. Absence of proper broker support available to the private investor! Can the board come up with a new ay of marketing the shares? I have been posting the same on here for years, much to the frustration of some here and on other BB's, but it really is obvious. Perhaps Eden will now listen to Michael Walters. Eden has no traction in the City in regards to buying a position in Eden. Powerscourt who are meant to further the same have made no visible gains. Thus, the Shore Cap report is useless as it falls on deaf ears and a blind audience. They are not looking to see. An independent report by the likes of Edison or whomever similar would have far greater applicable reach to an audience with ears and eyes that will listen, namely the private investor. Furthermore, they are always looking for capital growth and are only restrained by the £ in their pocket, but they will buy and will buy quickly if the story adds up. Shore Caps clients will of course not respond the same. What is the market cap (oh they're too small), they're on AIM (no good), we do invest in green stocks, but none so young as Eden. The reason are extensive and an investment is often a far more complicated decision. Not so with the private investor. Eden does need to find a new way of marketing the shares, but in the first place they need TO MARKET THE SHARES. Eden do not market their shares and their toe in the water with Proactive is merely a series of process updates, albeit well explained, but they never give an investor a reason to buy and consequently, they don't. Eden must surely have learned its lesson over the last 2-3 years in regards to gaining investment in its share price, whom to target, why and how. Everything they have done, which is limited, has failed to incentivise people to invest, but then they have not targeted people (private investors). Eden sits at a market cap of circa £22 million. The narrative and the price still don't align It costs $25-$30 million to deliver a biopesticde to market, so $50-$60 million in total, almost three times our current market cap. The Chairman in the 2018 Annual Report says "the new products in the Company's pipeline aim to address markets which are potentially even bigger that those already covered by its existing products" Also he states " there is potential for an even greater opportunity around the use of Eden's proprietary, natural micro-encapsulation technology which is being teste by a number of third parties including some of the major agchem companies" Where is any of this in a three year forecast from the Company? How is this potential communicated to an investment public outside of this written word in the Annual Report. More importantly, how many people received a hard copy of the Annual Report and how many read/downloaded the PDF. Eden only talks to a few existing investors who are listening. The rest are asleep and the rest of their target audience has no idea who Eden is or the breakthroughs they are making. I very much doubt those not invested in Eden are reading our RNS's, why would they?! So MW is right, find a way to market Eden's shares to an audience that is willing to invest, willing to listen, available to listen and who equally importantly, will be your bag carrier of opportunity to other investors. In my opinion, if we sit here waiting for Powerscourt or a broker to unlock the door then Eden's shares will likely be dormant for some while to come. Finally and for Powerscourt, the world now seems to really understand that Pesticides are bad for you. Eat fruit, veg and nuts everyone; oh dear, they've been treated with pesticides, so maybe 5-a day is not as good for you as we suggested. Eden has a major PR opportunity right in the eye of the storm when readers will listen, journalists will listen and knock on Eden's door, doors will open for Powerscourt as a result of the same, the public will go to Eden's website to find out more, hey they might even invest. Why is Eden not challenging this when their share price is so low, their company value is so undervalued and the newspaper public, I'm sure, would love to hear about them. And it has nothing to do with a small employee base! Eden, one of only a few biocontrol companies globally with proven products and regulatory approval and yet, the investment world knows nothing about it!!!!!
investingisatrickygame
15/5/2019
15:06
Eden, the Snail in the Garden I see Michael Walters has it spot on this time. There is a great deal of frustration around the Eden share price! The problem is that Eden is not allowed to tell common garden investors what is in the shore cap report even though as owners of the company we have paid for it via fees to the brokers! Fairly basic Proactive chats are no substitutions for real projections (that we all can see. Absence of proper broker support available to the private investor! Can the board come up with a new ay of marketing the shares? I have been posting the same on here for years, much to the frustration of some here and on other BB's, but it really is obvious. Perhaps Eden will now listen to Michael Walters. Eden has no traction in the City in regards to buying a position in Eden. Powerscourt who are meant to further the same have made no visible gains. Thus, the Shore Cap report is useless as it falls on deaf ears and a blind audience. They are not looking to see. An independent report by the likes of Edison or whomever similar would have far greater applicable reach to an audience with ears and eyes that will listen, namely the private investor. Furthermore, they are always looking for capital growth and are only restrained by the £ in their pocket, but they will buy and will buy quickly if the story adds up. Shore Caps clients will of course not respond the same. What is the market cap (oh they're too small), they're on AIM (no good), we do invest in green stocks, but none so young as Eden. The reason are extensive and an investment is often a far more complicated decision. Not so with the private investor. Eden does need to find a new way of marketing the shares, but in the first place they need TO MARKET THE SHARES. Eden do not market their shares and their toe in the water with Proactive is merely a series of process updates, albeit well explained, but they never give an investor a reason to buy and consequently, they don't. Eden must surely have learned its lesson over the last 2-3 years in regards to gaining investment in its share price, whom to target, why and how. Everything they have done, which is limited, has failed to incentivise people to invest, but then they have not targeted people (private investors). Eden sits at a market cap of circa £22 million. The narrative and the price still don't align It costs $25-$30 million to deliver a biopesticde to market, so $50-$60 million in total, almost three times our current market cap. The Chairman in the 2018 Annual Report says "the new products in the Company's pipeline aim to address markets which are potentially even bigger that those already covered by its existing products" Also he states " there is potential for an even greater opportunity around the use of Eden's proprietary, natural micro-encapsulation technology which is being teste by a number of third parties including some of the major agchem companies" Where is any of this in a three year forecast from the Company? How is this potential communicated to an investment public outside of this written word in the Annual Report. More importantly, how many people received a hard copy of the Annual Report and how many read/downloaded the PDF. Eden only talks to a few existing investors who are listening. The rest are asleep and the rest of their target audience has no idea who Eden is or the breakthroughs they are making. I very much doubt those not invested in Eden are reading our RNS's, why would they?! So MW is right, find a way to market Eden's shares to an audience that is willing to invest, willing to listen, available to listen and who equally importantly, will be your bag carrier of opportunity to other investors. In my opinion, if we sit here waiting for Powerscourt or a broker to unlock the door then Eden's shares will likely be dormant for some while to come. Finally and for Powerscourt, the world now seems to really understand that Pesticides are bad for you. Eat fruit, veg and nuts everyone; oh dear, they've been treated with pesticides, so maybe 5-a day is not as good for you as we suggested. Eden has a major PR opportunity right in the eye of the storm when readers will listen, journalists will listen and knock on Eden's door, doors will open for Powerscourt as a result of the same, the public will go to Eden's website to find out more, hey they might even invest. Why is Eden not challenging this when their share price is so low, their company value is so undervalued and the newspaper public, I'm sure, would love to hear about them. And it has nothing to do with a small employee base! Eden, one of only a few biocontrol companies globally with proven products and regulatory approval and yet, the investment world knows nothing about it!!!!!
investingisatrickygame
15/5/2019
08:21
Eastman are obviously interested in Sustaine via Cedroz and their statement also suggests they are impressed - Cedroz™ post-planting nematicide—where chemistry meets nature. This innovative system promotes suspensibility without the use of emulsion solvents. Once applied to the soil, the capsules provide modulated and gradual release of the two terpenes through the microporosity of the capsule wall. hTTps://www.eastman.com/Pages/Cedroz-Overview.aspx That final statement is also another reason for me to believe that Sustaine can indeed be effectively utilised in the seed treatment market. So, I think it is highly likely that Eastman are one of the interested parties referred to that are testing and evaluating Sustaine, especially given their knowledge gained during the development of Cedroz (not to mention their investment and regulatory push!). Interestingly, Eastman have their own terpene-based formulations/products (and are launching an enhanced formulation with a wider window of application for another product) - hTTps://www.eastman.com/Markets/agricultural/Crop-Protection/Pages/Growth-regulators.aspx Given the regulatory backdrop, it is also interesting to look at some of Eastman's products from this perspective. The following list of endocrine disrupting chemicals provides food for thought given that there are a number of key Eastman crop protection products on the list. hTTps://chemicalwatch.com/68296/un-publishes-list-of-identified-endocrine-disruptors Take Thiram and Ziram for example. The Commission Implementing Regulation (EU) 2018/1500 concerns the non-renewal of approval for the active substance thiram and also prohibits the use and sale of seeds treated with plant protection products containing thiram. Plant protection products containing this active substance have been withdrawn with a phased-withdrawal date ending January 30, 2019 and a for sale and distribution date of January 30, 2020, for disposal, storage and use. hTTps://www.eastman.com/Markets/agricultural/Crop-Protection/Pages/Fungicides.aspx hTTps://www.eastman.com/Markets/agricultural/Crop-Protection/Pages/Seed-treatment.aspx This of course is no guarantee that Eastman are one of the mentioned parties or that a deal is imminent, but other global players and indeed farmers are in a similar situation with regard to a shrinking chemical toolbox. And Sustaine certainly appears to have the potential of at least helping to address the situation, including the potential of 'delivering' chemicals and biologicals together.
wan
15/5/2019
06:39
Why Expectations are High Regarding Biological Products By John Njiraini|14 May 2019 The need to reduce chemical use is driving the uptake of biologicals. While the industry has a long way to go before it can match the success of traditional synthetic crop protection products, its growing influence in the market cannot be ignored. AgriBusiness Global™ magazine spoke with Thomas Mason, the President of BioProtection Global, on issues facing the industry: Q&A follows - hTTps://www.agribusinessglobal.com/biopesticides/why-expectations-are-high-regarding-biological-products/ There are some interesting points and the last answer stood out, as it included the need to improve delivery technologies......cue Eden's Sustaine and indeed IPM - Q. What’s the future or biologicals? The biological sector will grow at an even faster rate in the coming years. The focus should be on understanding how we can make our solutions more effective and more precise. We also need to improve delivery methods, de-complicate their use, and focus on the roles that chemicals and biologicals play together.
wan
14/5/2019
15:00
AttyG 14 May '19 - 15:22 - 442 of 442 0 0 0 In some ways it is possibly difficult to beef up the presentation much from last year - but to a casual reader, not a lot has changed. The best bit for me is Slide 23 "Key crops expected to grow from one to more than ten in the nest three years." If that happens, the share price will be able to look after itself. ------------------------------------------------------------------ Atty, agreed on all points. But will be interesting to see what account the CEO gave of himself and the company this afternoon.
brucie5
14/5/2019
14:22
In some ways it is possibly difficult to beef up the presentation much from last year - but to a casual reader, not a lot has changed. The best bit for me is Slide 23 "Key crops expected to grow from one to more than ten in the nest three years." If that happens, the share price will be able to look after itself. Sadly the share price could do with a bit of help at the moment! Silence on Bayer and TT - or did I skim through too quickly?
attyg
14/5/2019
14:21
wan, Have you attended the AGM today? If so, what questions and answers were there relevant to the share price and managements recognition that fair value reflected in the share price is part of their role in managing a Plc? Was management pushed on poor performance in relation to the same? Did management give any answers on the Sustaine trials with Sipcam products as no updates whatsoever in two years? How would you assess the interaction between management and shareholders present? This presentation is lazy in that is it just a rehash of the Proactive evening, save a few comments around pesticides from newspaper articles.
investingisatrickygame
14/5/2019
14:02
Addressable ' future ' market updated to 4bn. But what does that mean? Eg. How does it differ from 'tomorrow'? Sorry to be pernickety. !!!!!!
brucie5
14/5/2019
13:51
AGM Presentation - hTTp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/agm-presentation-2019.pdf
wan
14/5/2019
08:51
It will be interesting to see if the "emergency use" authorisation in Italy for Mevalone addressing Botrytis on kiwifruit (not reported by Eden, but highlighted in post 409) eventually gets cited. Because as per the Cedroz emergency authorisation, it also implies the lack of a suitable alternative, highlights the proven efficacy provided by Mevalone and indeed highlights the significance of the kiwifruit market! hTTp://www.sipcamitalia.it/it/fungicidi/25/3logy/X/16396 kiwifruit represents a sizeable and important market in Italy, and Italy are the global number two exporter of kiwifruit - Kiwifruit Exports by Country JULY 10, 2018 BY DANIEL WORKMAN Below are the 15 countries that exported the highest dollar value worth of kiwifruit during 2017. 1. New Zealand: US$1.2 billion (43.6% of total kiwifruit exports) 2. Italy: $527.6 million (19.5%) 3. Belgium: $329.6 million (12.2%) 4. Chile: $188 million (6.9%) 5. Greece: $130.6 million (4.8%) hTTp://www.worldstopexports.com/kiwifruit-exports-by-country/
wan
14/5/2019
08:45
Old rhetoric Super. Possibly Investing, but in a rapidly evolving paradigm where the untouchables are getting their Hubris trashed and reputation publicly savaged, where the SustainabilityMegaTrend is being kicked up a gear or two, the statement and more importantly the products/technology has way more currency. Eden's time has come ...as you can see by the volume of trades today:)
supersonico
14/5/2019
08:37
Yes, major question is how they intend to effect the 'strategic change' that Wan speaks of. They have intimated they intend to bring in more staff: but this will require extra spend. So how will they do this without a further RI?
brucie5
14/5/2019
08:30
Oh dear! If they don’t indicate today how they ate going to immediately go into overdrive they will surely miss out. They have access to whatever Sipcam know from their lab but not the capability or personnel to exploit it or understand it. If they are not careful they will be superseded by all the competition just as Eastman stole a march on Sipcam in the short term
chrischas
14/5/2019
08:24
“No new material will be disclosed in the presentation” from today’s AGM statement. You have to ask ......what the point of Sean presenting it is then.
ipeesquint
14/5/2019
08:12
Clearly, Eden's expanding "footprint" will be a key driver going forwards, but I am still 'very' optimistic about label extensions to cover major new disease and other crop targets. For which Sipcam, the "exclusive" distributor, is obviously optimistic too in this regard ;-)
wan
14/5/2019
06:27
Old rhetoric Super. I hope they're delivering a lot more than that today.
investingisatrickygame
Chat Pages: Latest  286  285  284  283  282  281  280  279  278  277  276  275  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191210 02:02:21